Home
/
Mirum Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Mirum Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Mirum Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$133.01M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$127.79M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$111.59M
May 7, 2025
Q3
2025
Sep 30, 2024
$90.38M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$77.88M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$69.22M
May 7, 2025
Q3
2024
Sep 30, 2023
$47.73M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$37.50M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$31.60M
May 8, 2024
Q3
2023
Sep 30, 2022
$18.78M
Nov 2, 2023
Q2
2023
Jun 30, 2022
$17.48M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$12.89M
May 4, 2023
Q3
2022
Sep 30, 2021
$5.00M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$11.00M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$0
May 5, 2022
Q3
2021
Sep 30, 2020
$0
Nov 15, 2021
Q2
2021
Jun 30, 2020
$0
Aug 5, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.91M
Nov 4, 2025
Q3
2025
Jun 30, 2025
($5.86M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($5.86M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($14.68M)
Nov 4, 2025
Q2
2025
Mar 31, 2025
($14.68M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($14.68M)
May 7, 2025
Q3
2025
Sep 30, 2024
($14.24M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($24.64M)
Aug 6, 2025
Q3
2025
Jun 30, 2024
($24.64M)
Nov 4, 2025
Q1
2025
Mar 31, 2024
($25.28M)
May 7, 2025
Q2
2025
Mar 31, 2024
($25.28M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($25.28M)
Nov 4, 2025
Q3
2024
Sep 30, 2023
($23.59M)
Nov 12, 2024
Q3
2024
Jun 30, 2023
($74.04M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($74.04M)
Aug 7, 2024
Q3
2024
Mar 31, 2023
($30.13M)
Nov 12, 2024
Q1
2024
Mar 31, 2023
($30.13M)
May 8, 2024
Q2
2024
Mar 31, 2023
($30.13M)
Aug 7, 2024
Q3
2023
Sep 30, 2022
($35.71M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($26.92M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.60M
Nov 4, 2025
Q2
2025
Jun 30, 2025
($4.99M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($15.18M)
May 7, 2025
Q3
2025
Sep 30, 2024
($12.68M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($24.23M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($26.47M)
May 7, 2025
Q3
2024
Sep 30, 2023
($25.15M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($24.27M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($27.15M)
May 8, 2024
Q3
2023
Sep 30, 2022
($32.88M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($31.44M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($32.74M)
May 4, 2023
Q3
2022
Sep 30, 2021
($42.82M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($37.40M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($47.61M)
May 5, 2022
Q3
2021
Sep 30, 2020
($21.72M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($23.60M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($22.03M)
May 6, 2021
Q3
2020
Sep 30, 2019
($15.87M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($14.03M)
Aug 6, 2020